CAMBRIDGE, Mass.--(BUSINESS WIRE)--Correlagen Diagnostics, Inc., a leading developer of innovative molecular diagnostics, today announced the availability of a test that may help prevent death from early heart attacks. Six hundred thousand Americans have a genetic cause of high cholesterol that increases their risk of suffering heart attacks at a very young age up to 125 fold. With proper diagnosis and treatment, using a combination of targeted genetic testing and cholesterol-lowering drug therapy, heart attacks could be prevented in 200,000, and deaths in 50,000, of these individuals.
